ASX - Delayed Quote AUD

Dimerix Limited (DXB.AX)

0.7150

+0.0200

+(2.88%)

At close: 4:10:39 PM GMT+10

Dimerix and Amicus to commercialise DMX-200 in US

Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

Pharmaceutical Technology 7 days ago

DXB.AX
+2.88%

FOLD
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval Dimerix to receive US$30 million (~AU$48 million) upfront payment, up to US$560 million (~AU$892 million) for success-based miles

GlobeNewswire 7 days ago

SBMJF

FOLD
FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS

In the Phase III trial, 183 out of 286 subjects have already been randomised/dosed.

Clinical Trials Arena 9 days ago

DXB.AX
+2.88%
3 ASX Penny Stocks With Market Caps Under A$500M

The Australian stock market recently demonstrated resilience, with the ASX climbing above the 7,800 points level despite mixed performances in global markets. In such a landscape, investors often seek out smaller or newer companies that can offer unique growth opportunities. Although "penny stocks" may sound like an outdated term, these stocks represent potential value investments; when backed by strong financials and fundamentals, they can provide significant upside potential.

Simply Wall St. 20 days ago

SXL.AX

SBMJF

SVMLF
ASX Penny Stocks To Watch In March 2025

The Australian stock market recently saw the ASX200 close down by 0.4% at 7,828 points, with Health Care and Telecommunication sectors showing resilience while Utilities and Real Estate lagged behind. In this context, penny stocks—often seen as a niche investment area—still hold potential for investors seeking growth opportunities in smaller or newer companies. Despite their somewhat outdated label, these stocks can offer significant returns when backed by strong financial health; we'll...

Simply Wall St. last month

SBMJF

IUGNF

JDO.AX
Companies Like Dimerix (ASX:DXB) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Dimerix ( ASX:DXB...

Simply Wall St. 5 months ago

SBMJF
Dimerix Full Year 2024 Earnings: AU$0.038 loss per share (vs AU$0.042 loss in FY 2023)

Dimerix ( ASX:DXB ) Full Year 2024 Results Key Financial Results Net loss: AU$17.1m (loss widened by 24% from FY 2023...

Simply Wall St. 8 months ago

DXB.AX
+2.88%

DXBO.AX
Dimerix and Taiba enter DMX-200 commercialisation deal in Middle East

Taiba will oversee the complete sales and expenditures linked to the marketing of the product.

Pharmaceutical Technology 11 months ago

DXB.AX
+2.88%
Dimerix (ASX:DXB) shareholders have earned a 359% return over the last year

For many, the main point of investing in the stock market is to achieve spectacular returns. When an investor finds a...

Simply Wall St. 11 months ago

DXB.AX
+2.88%

DXBO.AX

Performance Overview

Return	DXB.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	+110.29%	+0.40%
1-Year	+113.43%	+4.96%
3-Year	+459.77%	+13.69%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dimerix Limited (DXB.AX)

Dimerix and Amicus to commercialise DMX-200 in US

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS

3 ASX Penny Stocks With Market Caps Under A$500M

ASX Penny Stocks To Watch In March 2025

Companies Like Dimerix (ASX:DXB) Can Afford To Invest In Growth

Dimerix Full Year 2024 Earnings: AU$0.038 loss per share (vs AU$0.042 loss in FY 2023)

Dimerix and Taiba enter DMX-200 commercialisation deal in Middle East

Dimerix (ASX:DXB) shareholders have earned a 359% return over the last year

Performance Overview